‘Y’tube: UroLift placement

At a median follow-up of 44.8 months, median DFS in the pembrolizumab arm was 29.6 months vs 14.2 months in the observation arm.

In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.

Median OS was 35.0 months in the enzalutamide-alone arm vs 42.3 months in the combination arm.

In this episode of Speaking of Urology®, Eugene Rhee, MD, MBA, and Logan Galansky, MD, discuss key topics in health policy and recap the AUA's recent Annual Urology Advocacy Summit.

“NKT2152 demonstrated robust anti-tumor activity in a heavily pretreated, high-risk advanced clear cell renal cell carcinoma population," said Eric Jonasch, MD.

Investigators observed promising clinical effect with the EGFR / HER3 bispecific antibody-drug conjugate.